Study of NS-863 for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a certain type of PAH (Group 1), such as idiopathic, heritable, or related to drugs, connective tissue disease, or repaired congenital heart disease.
- Your symptoms are class II, III, or IV according to the WHO functional classification, and you are on stable background therapy.
- You can walk at least a short distance in 6 minutes (the test used to measure exercise capacity).
- You are willing to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This trial tests whether adding the study drug CS1 to your usual PAH treatment helps improve symptoms and daily function. It is for people with moderate symptoms who are already on stable PAH therapy.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
This trial tests an investigational drug called NS-863 for people who have both interstitial lung disease (scarring of the lungs) and pulmonary hypertension (high blood pressure in the lungs). The goal is to see if the drug can help improve your condition.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.